Now Playing
|Videos|January 23, 2023
Case Presentation: A 55-Year-Old Man with Muscle-Invasive Bladder Cancer (MIBC)
Author(s)Matthew Galsky, MD
Matthew Galsky, MD, presents the case of a 55-year-old man with stage T2N0M0 muscle-invasive bladder cancer (MIBC) for review, and explains how cisplatin eligibility is defined in patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5